The authors conducted a prospective trial to assess the feasibility of real time central
molecular assessment of kidney transplant biopsy samples from 10 North American or
European centers. Biopsy samples taken 1 day to 34 years posttransplantation were
stabilized in RNAlater, sent via courier overnight at ambient temperature to the central
laboratory, and processed (29 h workflow) using microarrays to assess T cell–and antibody-
mediated rejection (TCMR and ABMR, respectively). Of 538 biopsy samples submitted, 519 …